Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
Nab Paclitor is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Metastatic Breast Cancer
Nab-Paclitaxel is used after combination chemotherapy has failed for metastatic breast cancer, or when the cancer has relapsed within 6 months of adjuvant chemotherapy. The recommended regimen is 260 mg/m² given intravenously over 30 minutes every 3 weeks.
Non-Small Cell Lung Cancer
The recommended dose is 100 mg/m², given as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of each 21-day cycle. Carboplatin is given on Day 1 of each 21 day cycle, immediately after the Nab-Paclitaxel.
Adenocarcinoma Of The Pancreas
The recommended dose is 125 mg/m², given as an intravenous infusion over 30 to 40 minutes on Days 1, 8 and 15 of each 28-day cycle. Gemcitabine follows immediately after the infusion on Days 1, 8 and 15 of each 28-day cycle.
Dosage In Patients With Hepatic Impairment
For patients with mild hepatic impairment (total bilirubin greater than ULN and less than or equal to 1.5 x ULN, and aspartate aminotransferase [AST] less than or equal to 10 x ULN), no dose adjustment is required, whatever the indication.
Don't give Nab-Paclitaxel to patients with metastatic adenocarcinoma of the pancreas who have moderate to severe hepatic impairment. Don't give it either to patients with total bilirubin greater than 5 x ULN or AST greater than 10 x ULN, whatever the indication, because these patients have not been studied.
Side Effects
When Nab-Paclitaxel [Nanoparticle Albumin-Bound Paclitaxel] is used alone for metastatic breast cancer, the most common adverse reactions (≥20%) are alopecia, neutropenia, sensory neuropathy, abnormal ECG, fatigue/asthenia, myalgia/arthralgia, AST elevation, alkaline phosphatase elevation, anemia, nausea, infections and diarrhea. For non-small cell lung cancer, Nab-Paclitaxel is given together with carboplatin. In that combination, the most common adverse reactions (≥20%) are anemia, neutropenia, thrombocytopenia, alopecia, peripheral neuropathy, nausea and fatigue. The most common serious adverse reactions are anemia (4%) and pneumonia (3%). The adverse reactions that most often lead to permanent discontinuation of Nab-Paclitaxel are neutropenia (3%), thrombocytopenia (3%) and peripheral neuropathy (1%). Those that most often lead to a dose reduction are neutropenia (24%), thrombocytopenia (13%) and anemia (6%). Those that most often lead to the dose being withheld or delayed are neutropenia (41%), thrombocytopenia (30%) and anemia (16%).
Cautions & Contraindications
Contraindications
Nab-Paclitaxel should not be given to patients whose baseline neutrophil count is below 1,500 cells/mm³. It should also not be given again to any patient who has had a severe hypersensitivity reaction to Nab-Paclitaxel, so no rechallenge with the drug.
Pregnancy & Breastfeeding
Nab-Paclitaxel is Pregnancy Category D, which means it can cause harm to the baby when given to a pregnant woman. In rats, albumin-bound paclitaxel given during pregnancy at doses lower than the maximum recommended human dose (based on body surface area) caused toxicity to the embryo and fetus. This included intrauterine mortality, increased resorptions, fewer live fetuses and malformations.
There are no adequate and well-controlled studies in pregnant women taking Nab-Paclitaxel. If the medicine is used during pregnancy, or if a patient becomes pregnant while on it, she should be told about the possible hazard to the baby. Women who could become pregnant should be advised to avoid pregnancy while receiving Nab-Paclitaxel.
It is not known whether paclitaxel passes into human milk. In lactating rats, paclitaxel and/or its metabolites were found in the milk. Many drugs pass into human milk, and nursing infants could have serious adverse reactions. So a decision should be made either to stop nursing or to stop the drug, taking into account how important the drug is to the mother.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Use in Special Populations
Pediatric Use: The safety and effectiveness of Nab-Paclitaxel [Nanoparticle Albumin-Bound Paclitaxel] in pediatric patients have not been evaluated.
Geriatric Use: In the randomized study in metastatic breast cancer, 229 patients received the medicine. Of these, 13% were at least 65 years of age and < 2% were 75 years or older. No toxicity occurred clearly more often in the patients who received Nab-Paclitaxel.
A later pooled analysis looked at 981 patients who received Nab-Paclitaxel as monotherapy for metastatic breast cancer. In this group 15% were 65 years of age or older and 2% were 75 years of age or older. Epistaxis, diarrhea, dehydration, fatigue and peripheral edema were found more often in patients 65 years of age or older.
In the randomized study of first-line treatment of non-small cell lung cancer, 514 patients received Nab-Paclitaxel with carboplatin. Of these, 31% were 65 years or older and 3.5% were 75 years or older. Myelosuppression, peripheral neuropathy and arthralgia were more frequent in patients 65 years or older than in patients younger than 65 years. There was no overall difference in effectiveness between the two age groups, as measured by response rates.
In the randomized study of first-line treatment of pancreatic adenocarcinoma, 431 patients received Nab-Paclitaxel with gemcitabine. Of these, 41% were 65 years or older and 10% were 75 years or older. No overall differences in effectiveness were seen between patients 65 years of age or older and younger patients. Diarrhea, decreased appetite, dehydration and epistaxis were more frequent in patients 65 years or older than in patients younger than 65 years. The clinical studies did not include enough pancreatic cancer patients aged 75 years and older to show whether they respond differently from younger patients.
Patients With Hepatic Impairment: Exposure to paclitaxel may be higher in patients with hepatic impairment than in patients with normal hepatic function. The starting dose should be reduced in patients with moderate to severe hepatic impairment. Do not give Nab-Paclitaxel to patients with total bilirubin > 5 x ULN or AST > 10 x ULN. Do not give it to patients with metastatic adenocarcinoma of the pancreas who have moderate to severe hepatic impairment.
Patients With Renal Impairment: The starting dose does not need adjusting in patients with mild to moderate renal impairment (estimated creatinine clearance ≥ 30 to < 90 mL/min). For patients with severe renal impairment or end stage renal disease (estimated creatinine clearance < 30 mL/min), there are not enough data to make dosage recommendations.
Overdose
There is no known antidote if someone gets too much Nab-Paclitaxel [Nanoparticle Albumin-Bound Paclitaxel]. The main complications expected from an overdose are bone marrow suppression, sensory neurotoxicity and mucositis.
⚠️ In an emergency call 999 or go to the nearest hospital emergency department.
Storage
Keep the Nab-Paclitaxel vials in their original cartons at 20°C to 25°C. The carton protects them from bright light, so leave them in it.
Drug Interactions
Common questions about Nab Paclitor 100 mg
What is Nab Paclitor 100 mg IV Infusion?
Nab Paclitor 100 mg IV Infusion is a medicine that contains Nab-Paclitaxel [Nanoparticle Albumin-Bound Paclitaxel]. It is made by Eskayef Pharmaceuticals Ltd. It belongs to the Cytotoxic Chemotherapy group of medicines.
What is Nab Paclitor used for?
Nab Paclitor is used for: Cancer.
What are the side effects of Nab Paclitor?
When Nab-Paclitaxel [Nanoparticle Albumin-Bound Paclitaxel] is used alone for metastatic breast cancer, the most common adverse reactions (≥20%) are alopecia, neutropenia, sensory neuropathy, abnormal ECG, fatigue/asthenia, myalgia/arthralgia, AST elevation, alkaline phosphatase elevation, anemia, nausea, infections and diarrhea. For non-small cell lung cancer, Nab-Paclitaxel is given together with carboplatin.
Can I take Nab Paclitor during pregnancy or while breastfeeding?
Nab-Paclitaxel is Pregnancy Category D, which means it can cause harm to the baby when given to a pregnant woman. In rats, albumin-bound paclitaxel given during pregnancy at doses lower than the maximum recommended human dose (based on body surface area) caused toxicity to the embryo and fetus. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
What happens if I take too much Nab Paclitor?
There is no known antidote if someone gets too much Nab-Paclitaxel [Nanoparticle Albumin-Bound Paclitaxel]. The main complications expected from an overdose are bone marrow suppression, sensory neurotoxicity and mucositis. In an emergency call 999 or go to the nearest hospital emergency department.
How should I store Nab Paclitor?
Keep the Nab-Paclitaxel vials in their original cartons at 20°C to 25°C. The carton protects them from bright light, so leave them in it.
Can I take other medicines with Nab Paclitor?
Some medicines can interact with Nab-Paclitaxel [Nanoparticle Albumin-Bound Paclitaxel], for example: Erythromycin, Carbamazepine, Rifampicin, Paclitaxel, Cimetidine, Fluoxetine. Tell your doctor or pharmacist about every medicine you take.
Do I need a prescription for Nab Paclitor?
Nab Paclitor is a prescription (Rx) medicine. Take it as your doctor advises.